Central Bank & Trust Co. Reduces Stock Holdings in Zoetis Inc. $ZTS

Key Points

• Central Bank & Trust Co. has reduced its holdings in Zoetis Inc. by 20%, now owning 7,071 shares valued at $1,103,000 as of the latest SEC filing.
• Recent earnings showed Zoetis reported $1.76 EPS, surpassing estimates, with a quarterly revenue increase of 4.2% year-over-year.
• Analysts have mixed ratings on Zoetis, with five rating it as a Buy and four as Hold, currently holding an average price target of $200.88.

Central Bank & Trust Co. decreased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 20.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,071 shares of the company's stock after selling 1,764 shares during the quarter. Central Bank & Trust Co.'s holdings in Zoetis were worth $1,103,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZTS. Nova Wealth Management Inc. purchased a new position in shares of Zoetis in the 1st quarter worth approximately $25,000. 1248 Management LLC purchased a new position in Zoetis during the 1st quarter valued at $27,000. Saudi Central Bank purchased a new position in Zoetis during the 1st quarter valued at $29,000. Cornerstone Planning Group LLC boosted its holdings in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Zoetis by 87.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 1.3%

Shares of NYSE:ZTS opened at $146.34 on Tuesday. The business's 50-day moving average is $152.10 and its 200 day moving average is $157.06. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The firm has a market capitalization of $64.85 billion, a P/E ratio of 25.19, a P/E/G ratio of 2.38 and a beta of 0.89. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period in the prior year, the company posted $1.56 EPS. The firm's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ZTS shares. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, Argus reiterated a "buy" rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.